nodes	percent_of_prediction	percent_of_DWPC	metapath
Bumetanide—SLCO1A2—Chlorambucil—ovarian cancer	0.386	0.739	CbGbCtD
Bumetanide—SLC22A7—Docetaxel—ovarian cancer	0.137	0.261	CbGbCtD
Bumetanide—PTGS2—ovarian follicle—ovarian cancer	0.0117	0.0662	CbGeAlD
Bumetanide—Diuresis—Vinorelbine—ovarian cancer	0.00877	0.0347	CcSEcCtD
Bumetanide—SLC12A4—embryo—ovarian cancer	0.0083	0.047	CbGeAlD
Bumetanide—Hypochloraemia—Epirubicin—ovarian cancer	0.00676	0.0267	CcSEcCtD
Bumetanide—SLC12A4—uterine cervix—ovarian cancer	0.00671	0.038	CbGeAlD
Bumetanide—Electrolyte imbalance—Vinorelbine—ovarian cancer	0.00651	0.0257	CcSEcCtD
Bumetanide—Hypochloraemia—Doxorubicin—ovarian cancer	0.00626	0.0247	CcSEcCtD
Bumetanide—CA5A—female reproductive system—ovarian cancer	0.00585	0.0331	CbGeAlD
Bumetanide—SLC12A4—gonad—ovarian cancer	0.00563	0.0319	CbGeAlD
Bumetanide—SLC12A4—uterus—ovarian cancer	0.00559	0.0317	CbGeAlD
Bumetanide—CFTR—epithelium—ovarian cancer	0.00532	0.0301	CbGeAlD
Bumetanide—SLC12A4—female reproductive system—ovarian cancer	0.00503	0.0285	CbGeAlD
Bumetanide—SLC12A5—testis—ovarian cancer	0.00489	0.0277	CbGeAlD
Bumetanide—SLC12A2—epithelium—ovarian cancer	0.00467	0.0265	CbGeAlD
Bumetanide—SLC12A4—female gonad—ovarian cancer	0.00458	0.0259	CbGeAlD
Bumetanide—SLC12A2—decidua—ovarian cancer	0.00441	0.025	CbGeAlD
Bumetanide—Electrolyte imbalance—Paclitaxel—ovarian cancer	0.00438	0.0173	CcSEcCtD
Bumetanide—SLC12A2—endometrium—ovarian cancer	0.00419	0.0237	CbGeAlD
Bumetanide—SLC12A4—testis—ovarian cancer	0.00406	0.023	CbGeAlD
Bumetanide—CFTR—female reproductive system—ovarian cancer	0.00395	0.0224	CbGeAlD
Bumetanide—Vertigo—Altretamine—ovarian cancer	0.00395	0.0156	CcSEcCtD
Bumetanide—Leukopenia—Altretamine—ovarian cancer	0.00393	0.0155	CcSEcCtD
Bumetanide—SLC12A1—epithelium—ovarian cancer	0.00392	0.0222	CbGeAlD
Bumetanide—SLC12A2—gonad—ovarian cancer	0.00389	0.022	CbGeAlD
Bumetanide—Hyperuricaemia—Chlorambucil—ovarian cancer	0.00385	0.0152	CcSEcCtD
Bumetanide—SLC10A1—gonad—ovarian cancer	0.00367	0.0208	CbGeAlD
Bumetanide—Blood uric acid increased—Chlorambucil—ovarian cancer	0.00364	0.0144	CcSEcCtD
Bumetanide—CFTR—female gonad—ovarian cancer	0.00359	0.0204	CbGeAlD
Bumetanide—Thrombocytopenia—Altretamine—ovarian cancer	0.00351	0.0139	CcSEcCtD
Bumetanide—SLC12A2—female reproductive system—ovarian cancer	0.00347	0.0197	CbGeAlD
Bumetanide—CA9—female reproductive system—ovarian cancer	0.00342	0.0194	CbGeAlD
Bumetanide—Hyperuricaemia—Melphalan—ovarian cancer	0.00336	0.0133	CcSEcCtD
Bumetanide—SLC10A1—female reproductive system—ovarian cancer	0.00328	0.0186	CbGeAlD
Bumetanide—SLC12A2—bone marrow—ovarian cancer	0.00328	0.0186	CbGeAlD
Bumetanide—CFTR—testis—ovarian cancer	0.00319	0.0181	CbGeAlD
Bumetanide—Blood uric acid increased—Melphalan—ovarian cancer	0.00317	0.0125	CcSEcCtD
Bumetanide—SLC12A2—female gonad—ovarian cancer	0.00316	0.0179	CbGeAlD
Bumetanide—SLC12A2—vagina—ovarian cancer	0.00314	0.0178	CbGeAlD
Bumetanide—Hepatocellular injury—Melphalan—ovarian cancer	0.00311	0.0123	CcSEcCtD
Bumetanide—Fatigue—Altretamine—ovarian cancer	0.00309	0.0122	CcSEcCtD
Bumetanide—SLC22A11—female reproductive system—ovarian cancer	0.00299	0.017	CbGeAlD
Bumetanide—SLC12A4—lymph node—ovarian cancer	0.00294	0.0167	CbGeAlD
Bumetanide—Hearing impaired—Vinorelbine—ovarian cancer	0.00286	0.0113	CcSEcCtD
Bumetanide—Encephalopathy—Paclitaxel—ovarian cancer	0.00285	0.0113	CcSEcCtD
Bumetanide—SLC12A2—testis—ovarian cancer	0.0028	0.0159	CbGeAlD
Bumetanide—CA9—testis—ovarian cancer	0.00276	0.0156	CbGeAlD
Bumetanide—SLC10A1—testis—ovarian cancer	0.00265	0.015	CbGeAlD
Bumetanide—Asthenia—Altretamine—ovarian cancer	0.00257	0.0102	CcSEcCtD
Bumetanide—CA5B—gonad—ovarian cancer	0.00254	0.0144	CbGeAlD
Bumetanide—CA12—female reproductive system—ovarian cancer	0.00253	0.0143	CbGeAlD
Bumetanide—Dizziness—Altretamine—ovarian cancer	0.00237	0.00937	CcSEcCtD
Bumetanide—SLC22A7—testis—ovarian cancer	0.00236	0.0134	CbGeAlD
Bumetanide—SLC12A1—testis—ovarian cancer	0.00235	0.0133	CbGeAlD
Bumetanide—Toxic epidermal necrolysis—Chlorambucil—ovarian cancer	0.00233	0.00922	CcSEcCtD
Bumetanide—Vomiting—Altretamine—ovarian cancer	0.00228	0.00901	CcSEcCtD
Bumetanide—Hyponatraemia—Melphalan—ovarian cancer	0.00227	0.00897	CcSEcCtD
Bumetanide—CA5B—female reproductive system—ovarian cancer	0.00227	0.0128	CbGeAlD
Bumetanide—Polyuria—Vinorelbine—ovarian cancer	0.00225	0.00888	CcSEcCtD
Bumetanide—Blood disorder—Paclitaxel—ovarian cancer	0.00219	0.00866	CcSEcCtD
Bumetanide—Nausea—Altretamine—ovarian cancer	0.00213	0.00842	CcSEcCtD
Bumetanide—Cramp muscle—Topotecan—ovarian cancer	0.00208	0.00821	CcSEcCtD
Bumetanide—CA5B—vagina—ovarian cancer	0.00205	0.0116	CbGeAlD
Bumetanide—SLC12A2—lymph node—ovarian cancer	0.00203	0.0115	CbGeAlD
Bumetanide—Hyponatraemia—Vinorelbine—ovarian cancer	0.00198	0.00783	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Chlorambucil—ovarian cancer	0.00198	0.00783	CcSEcCtD
Bumetanide—Hearing impaired—Paclitaxel—ovarian cancer	0.00192	0.00759	CcSEcCtD
Bumetanide—Musculoskeletal pain—Paclitaxel—ovarian cancer	0.00185	0.00732	CcSEcCtD
Bumetanide—Blood creatinine increased—Vinorelbine—ovarian cancer	0.00185	0.00731	CcSEcCtD
Bumetanide—CA5B—testis—ovarian cancer	0.00183	0.0104	CbGeAlD
Bumetanide—Sweating—Topotecan—ovarian cancer	0.00171	0.00674	CcSEcCtD
Bumetanide—Serum creatinine increased—Epirubicin—ovarian cancer	0.0017	0.00672	CcSEcCtD
Bumetanide—Erythema multiforme—Chlorambucil—ovarian cancer	0.0017	0.0067	CcSEcCtD
Bumetanide—Pancreatitis—Vinorelbine—ovarian cancer	0.00167	0.00661	CcSEcCtD
Bumetanide—PTGS2—myometrium—ovarian cancer	0.00164	0.00931	CbGeAlD
Bumetanide—Hearing impaired—Docetaxel—ovarian cancer	0.00163	0.00644	CcSEcCtD
Bumetanide—PTGS2—embryo—ovarian cancer	0.00158	0.00895	CbGeAlD
Bumetanide—Serum creatinine increased—Doxorubicin—ovarian cancer	0.00157	0.00622	CcSEcCtD
Bumetanide—CA4—female reproductive system—ovarian cancer	0.00156	0.00887	CbGeAlD
Bumetanide—Hepatocellular injury—Docetaxel—ovarian cancer	0.00155	0.00613	CcSEcCtD
Bumetanide—Hyperventilation—Epirubicin—ovarian cancer	0.00152	0.00601	CcSEcCtD
Bumetanide—Polyuria—Paclitaxel—ovarian cancer	0.00151	0.00598	CcSEcCtD
Bumetanide—CA4—bone marrow—ovarian cancer	0.00148	0.00837	CbGeAlD
Bumetanide—SLCO1A2—testis—ovarian cancer	0.00143	0.00809	CbGeAlD
Bumetanide—CA4—female gonad—ovarian cancer	0.00142	0.00807	CbGeAlD
Bumetanide—Hyperventilation—Doxorubicin—ovarian cancer	0.00141	0.00556	CcSEcCtD
Bumetanide—Leukopenia—Chlorambucil—ovarian cancer	0.0014	0.00552	CcSEcCtD
Bumetanide—Muscle spasms—Topotecan—ovarian cancer	0.00134	0.00528	CcSEcCtD
Bumetanide—Hyponatraemia—Paclitaxel—ovarian cancer	0.00133	0.00527	CcSEcCtD
Bumetanide—CA5B—lymph node—ovarian cancer	0.00133	0.00751	CbGeAlD
Bumetanide—Glycosuria—Epirubicin—ovarian cancer	0.00129	0.0051	CcSEcCtD
Bumetanide—PTGS2—epithelium—ovarian cancer	0.00129	0.00731	CbGeAlD
Bumetanide—PTGS2—uterine cervix—ovarian cancer	0.00128	0.00724	CbGeAlD
Bumetanide—CA4—testis—ovarian cancer	0.00126	0.00716	CbGeAlD
Bumetanide—Blood disorder—Epirubicin—ovarian cancer	0.00125	0.00495	CcSEcCtD
Bumetanide—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00125	0.00493	CcSEcCtD
Bumetanide—Leukopenia—Topotecan—ovarian cancer	0.00124	0.00492	CcSEcCtD
Bumetanide—Blood creatinine increased—Paclitaxel—ovarian cancer	0.00124	0.00492	CcSEcCtD
Bumetanide—Liver injury—Epirubicin—ovarian cancer	0.00124	0.00491	CcSEcCtD
Bumetanide—Dehydration—Paclitaxel—ovarian cancer	0.00124	0.00488	CcSEcCtD
Bumetanide—Leukopenia—Melphalan—ovarian cancer	0.00122	0.00481	CcSEcCtD
Bumetanide—Hypokalaemia—Paclitaxel—ovarian cancer	0.00121	0.00478	CcSEcCtD
Bumetanide—Cramp muscle—Paclitaxel—ovarian cancer	0.0012	0.00473	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.0012	0.00473	CcSEcCtD
Bumetanide—Glycosuria—Doxorubicin—ovarian cancer	0.00119	0.00472	CcSEcCtD
Bumetanide—Chest pain—Topotecan—ovarian cancer	0.00118	0.00468	CcSEcCtD
Bumetanide—Arthralgia—Topotecan—ovarian cancer	0.00118	0.00468	CcSEcCtD
Bumetanide—Blood disorder—Doxorubicin—ovarian cancer	0.00116	0.00458	CcSEcCtD
Bumetanide—Chest pain—Melphalan—ovarian cancer	0.00116	0.00458	CcSEcCtD
Bumetanide—PTGS2—endometrium—ovarian cancer	0.00116	0.00655	CbGeAlD
Bumetanide—Liver injury—Doxorubicin—ovarian cancer	0.00115	0.00454	CcSEcCtD
Bumetanide—Hyponatraemia—Docetaxel—ovarian cancer	0.00113	0.00447	CcSEcCtD
Bumetanide—Hyperuricaemia—Epirubicin—ovarian cancer	0.00113	0.00446	CcSEcCtD
Bumetanide—Pancreatitis—Paclitaxel—ovarian cancer	0.00113	0.00445	CcSEcCtD
Bumetanide—Thrombocytopenia—Topotecan—ovarian cancer	0.00111	0.00439	CcSEcCtD
Bumetanide—Fatigue—Chlorambucil—ovarian cancer	0.0011	0.00434	CcSEcCtD
Bumetanide—Hyperhidrosis—Topotecan—ovarian cancer	0.0011	0.00433	CcSEcCtD
Bumetanide—Thrombocytopenia—Melphalan—ovarian cancer	0.00109	0.0043	CcSEcCtD
Bumetanide—Vertigo—Vinorelbine—ovarian cancer	0.00107	0.00422	CcSEcCtD
Bumetanide—PTGS2—uterus—ovarian cancer	0.00107	0.00604	CbGeAlD
Bumetanide—Blood uric acid increased—Epirubicin—ovarian cancer	0.00107	0.00421	CcSEcCtD
Bumetanide—Leukopenia—Vinorelbine—ovarian cancer	0.00106	0.00421	CcSEcCtD
Bumetanide—Musculoskeletal pain—Epirubicin—ovarian cancer	0.00106	0.00418	CcSEcCtD
Bumetanide—Dehydration—Docetaxel—ovarian cancer	0.00105	0.00414	CcSEcCtD
Bumetanide—Hepatocellular injury—Epirubicin—ovarian cancer	0.00105	0.00413	CcSEcCtD
Bumetanide—Hyperuricaemia—Doxorubicin—ovarian cancer	0.00104	0.00412	CcSEcCtD
Bumetanide—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00104	0.00412	CcSEcCtD
Bumetanide—Hypotension—Melphalan—ovarian cancer	0.00104	0.0041	CcSEcCtD
Bumetanide—Hyperglycaemia—Paclitaxel—ovarian cancer	0.00104	0.00409	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.00101	0.00401	CcSEcCtD
Bumetanide—Cramp muscle—Docetaxel—ovarian cancer	0.00101	0.00401	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.00101	0.00401	CcSEcCtD
Bumetanide—Urticaria—Chlorambucil—ovarian cancer	0.00101	0.004	CcSEcCtD
Bumetanide—Chest pain—Vinorelbine—ovarian cancer	0.00101	0.004	CcSEcCtD
Bumetanide—Arthralgia—Vinorelbine—ovarian cancer	0.00101	0.004	CcSEcCtD
Bumetanide—Abdominal pain—Chlorambucil—ovarian cancer	0.00101	0.00398	CcSEcCtD
Bumetanide—Renal failure—Paclitaxel—ovarian cancer	0.00101	0.00398	CcSEcCtD
Bumetanide—Blood uric acid increased—Doxorubicin—ovarian cancer	0.000986	0.00389	CcSEcCtD
Bumetanide—Musculoskeletal pain—Doxorubicin—ovarian cancer	0.00098	0.00387	CcSEcCtD
Bumetanide—Fatigue—Topotecan—ovarian cancer	0.000978	0.00386	CcSEcCtD
Bumetanide—Hepatocellular injury—Doxorubicin—ovarian cancer	0.000968	0.00382	CcSEcCtD
Bumetanide—PTGS2—female reproductive system—ovarian cancer	0.000958	0.00543	CbGeAlD
Bumetanide—Fatigue—Melphalan—ovarian cancer	0.000958	0.00378	CcSEcCtD
Bumetanide—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00095	0.00375	CcSEcCtD
Bumetanide—Gastrointestinal pain—Topotecan—ovarian cancer	0.000928	0.00367	CcSEcCtD
Bumetanide—CA4—lymph node—ovarian cancer	0.000915	0.00519	CbGeAlD
Bumetanide—Asthenia—Chlorambucil—ovarian cancer	0.000914	0.00361	CcSEcCtD
Bumetanide—Hypotension—Vinorelbine—ovarian cancer	0.000907	0.00358	CcSEcCtD
Bumetanide—PTGS2—bone marrow—ovarian cancer	0.000904	0.00512	CbGeAlD
Bumetanide—Pruritus—Chlorambucil—ovarian cancer	0.000902	0.00356	CcSEcCtD
Bumetanide—Urticaria—Topotecan—ovarian cancer	0.000901	0.00356	CcSEcCtD
Bumetanide—Abdominal pain—Topotecan—ovarian cancer	0.000897	0.00354	CcSEcCtD
Bumetanide—Urticaria—Melphalan—ovarian cancer	0.000882	0.00349	CcSEcCtD
Bumetanide—Diarrhoea—Chlorambucil—ovarian cancer	0.000872	0.00345	CcSEcCtD
Bumetanide—PTGS2—female gonad—ovarian cancer	0.000872	0.00494	CbGeAlD
Bumetanide—Erythema multiforme—Paclitaxel—ovarian cancer	0.000869	0.00343	CcSEcCtD
Bumetanide—PTGS2—vagina—ovarian cancer	0.000866	0.00491	CbGeAlD
Bumetanide—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00086	0.0034	CcSEcCtD
Bumetanide—Renal failure—Docetaxel—ovarian cancer	0.000853	0.00337	CcSEcCtD
Bumetanide—Fatigue—Vinorelbine—ovarian cancer	0.000837	0.00331	CcSEcCtD
Bumetanide—Asthenia—Topotecan—ovarian cancer	0.000814	0.00322	CcSEcCtD
Bumetanide—Vomiting—Chlorambucil—ovarian cancer	0.00081	0.0032	CcSEcCtD
Bumetanide—Pruritus—Topotecan—ovarian cancer	0.000803	0.00317	CcSEcCtD
Bumetanide—Asthenia—Melphalan—ovarian cancer	0.000797	0.00315	CcSEcCtD
Bumetanide—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000794	0.00314	CcSEcCtD
Bumetanide—Pruritus—Melphalan—ovarian cancer	0.000786	0.00311	CcSEcCtD
Bumetanide—Diarrhoea—Topotecan—ovarian cancer	0.000776	0.00307	CcSEcCtD
Bumetanide—Urticaria—Vinorelbine—ovarian cancer	0.000771	0.00305	CcSEcCtD
Bumetanide—Muscle spasms—Paclitaxel—ovarian cancer	0.000769	0.00304	CcSEcCtD
Bumetanide—Abdominal pain—Vinorelbine—ovarian cancer	0.000767	0.00303	CcSEcCtD
Bumetanide—Hyponatraemia—Epirubicin—ovarian cancer	0.000762	0.00301	CcSEcCtD
Bumetanide—Diarrhoea—Melphalan—ovarian cancer	0.00076	0.003	CcSEcCtD
Bumetanide—Nausea—Chlorambucil—ovarian cancer	0.000757	0.00299	CcSEcCtD
Bumetanide—Dizziness—Topotecan—ovarian cancer	0.00075	0.00296	CcSEcCtD
Bumetanide—Erythema multiforme—Docetaxel—ovarian cancer	0.000736	0.00291	CcSEcCtD
Bumetanide—Vomiting—Topotecan—ovarian cancer	0.000721	0.00285	CcSEcCtD
Bumetanide—Vertigo—Paclitaxel—ovarian cancer	0.000719	0.00284	CcSEcCtD
Bumetanide—Leukopenia—Paclitaxel—ovarian cancer	0.000716	0.00283	CcSEcCtD
Bumetanide—Rash—Topotecan—ovarian cancer	0.000715	0.00283	CcSEcCtD
Bumetanide—Dermatitis—Topotecan—ovarian cancer	0.000715	0.00282	CcSEcCtD
Bumetanide—Blood creatinine increased—Epirubicin—ovarian cancer	0.000711	0.00281	CcSEcCtD
Bumetanide—Headache—Topotecan—ovarian cancer	0.000711	0.00281	CcSEcCtD
Bumetanide—Vomiting—Melphalan—ovarian cancer	0.000706	0.00279	CcSEcCtD
Bumetanide—Dehydration—Epirubicin—ovarian cancer	0.000706	0.00279	CcSEcCtD
Bumetanide—Hyponatraemia—Doxorubicin—ovarian cancer	0.000705	0.00279	CcSEcCtD
Bumetanide—Rash—Melphalan—ovarian cancer	0.0007	0.00277	CcSEcCtD
Bumetanide—Dermatitis—Melphalan—ovarian cancer	0.0007	0.00276	CcSEcCtD
Bumetanide—Asthenia—Vinorelbine—ovarian cancer	0.000696	0.00275	CcSEcCtD
Bumetanide—Hypokalaemia—Epirubicin—ovarian cancer	0.000691	0.00273	CcSEcCtD
Bumetanide—Pruritus—Vinorelbine—ovarian cancer	0.000687	0.00271	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000684	0.0027	CcSEcCtD
Bumetanide—Chest pain—Paclitaxel—ovarian cancer	0.000681	0.00269	CcSEcCtD
Bumetanide—Arthralgia—Paclitaxel—ovarian cancer	0.000681	0.00269	CcSEcCtD
Bumetanide—Nausea—Topotecan—ovarian cancer	0.000674	0.00266	CcSEcCtD
Bumetanide—Dry mouth—Paclitaxel—ovarian cancer	0.000666	0.00263	CcSEcCtD
Bumetanide—Diarrhoea—Vinorelbine—ovarian cancer	0.000664	0.00262	CcSEcCtD
Bumetanide—Nausea—Melphalan—ovarian cancer	0.00066	0.00261	CcSEcCtD
Bumetanide—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000658	0.0026	CcSEcCtD
Bumetanide—Dehydration—Doxorubicin—ovarian cancer	0.000653	0.00258	CcSEcCtD
Bumetanide—Muscle spasms—Docetaxel—ovarian cancer	0.000652	0.00258	CcSEcCtD
Bumetanide—Pancreatitis—Epirubicin—ovarian cancer	0.000643	0.00254	CcSEcCtD
Bumetanide—Dizziness—Vinorelbine—ovarian cancer	0.000642	0.00254	CcSEcCtD
Bumetanide—Hypokalaemia—Doxorubicin—ovarian cancer	0.000639	0.00253	CcSEcCtD
Bumetanide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000639	0.00253	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000633	0.0025	CcSEcCtD
Bumetanide—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000631	0.00249	CcSEcCtD
Bumetanide—Vomiting—Vinorelbine—ovarian cancer	0.000617	0.00244	CcSEcCtD
Bumetanide—Rash—Vinorelbine—ovarian cancer	0.000612	0.00242	CcSEcCtD
Bumetanide—Dermatitis—Vinorelbine—ovarian cancer	0.000611	0.00242	CcSEcCtD
Bumetanide—Hypotension—Paclitaxel—ovarian cancer	0.00061	0.00241	CcSEcCtD
Bumetanide—Headache—Vinorelbine—ovarian cancer	0.000608	0.0024	CcSEcCtD
Bumetanide—Leukopenia—Docetaxel—ovarian cancer	0.000607	0.0024	CcSEcCtD
Bumetanide—Pancreatitis—Doxorubicin—ovarian cancer	0.000595	0.00235	CcSEcCtD
Bumetanide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000592	0.00234	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00058	0.00229	CcSEcCtD
Bumetanide—Chest pain—Docetaxel—ovarian cancer	0.000577	0.00228	CcSEcCtD
Bumetanide—Arthralgia—Docetaxel—ovarian cancer	0.000577	0.00228	CcSEcCtD
Bumetanide—Nausea—Vinorelbine—ovarian cancer	0.000576	0.00228	CcSEcCtD
Bumetanide—Renal failure—Epirubicin—ovarian cancer	0.000575	0.00227	CcSEcCtD
Bumetanide—Dry mouth—Docetaxel—ovarian cancer	0.000564	0.00223	CcSEcCtD
Bumetanide—Fatigue—Paclitaxel—ovarian cancer	0.000563	0.00222	CcSEcCtD
Bumetanide—Sweating—Epirubicin—ovarian cancer	0.000561	0.00222	CcSEcCtD
Bumetanide—PTGS2—lymph node—ovarian cancer	0.00056	0.00317	CbGeAlD
Bumetanide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000548	0.00216	CcSEcCtD
Bumetanide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000542	0.00214	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000537	0.00212	CcSEcCtD
Bumetanide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000534	0.00211	CcSEcCtD
Bumetanide—Renal failure—Doxorubicin—ovarian cancer	0.000532	0.0021	CcSEcCtD
Bumetanide—Sweating—Doxorubicin—ovarian cancer	0.000519	0.00205	CcSEcCtD
Bumetanide—Urticaria—Paclitaxel—ovarian cancer	0.000519	0.00205	CcSEcCtD
Bumetanide—Hypotension—Docetaxel—ovarian cancer	0.000517	0.00204	CcSEcCtD
Bumetanide—Abdominal pain—Paclitaxel—ovarian cancer	0.000516	0.00204	CcSEcCtD
Bumetanide—Erythema multiforme—Epirubicin—ovarian cancer	0.000497	0.00196	CcSEcCtD
Bumetanide—Fatigue—Docetaxel—ovarian cancer	0.000477	0.00188	CcSEcCtD
Bumetanide—Asthenia—Paclitaxel—ovarian cancer	0.000468	0.00185	CcSEcCtD
Bumetanide—Pruritus—Paclitaxel—ovarian cancer	0.000462	0.00182	CcSEcCtD
Bumetanide—Erythema multiforme—Doxorubicin—ovarian cancer	0.00046	0.00182	CcSEcCtD
Bumetanide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000452	0.00179	CcSEcCtD
Bumetanide—Diarrhoea—Paclitaxel—ovarian cancer	0.000447	0.00176	CcSEcCtD
Bumetanide—Muscle spasms—Epirubicin—ovarian cancer	0.00044	0.00174	CcSEcCtD
Bumetanide—Abdominal pain—Docetaxel—ovarian cancer	0.000437	0.00173	CcSEcCtD
Bumetanide—Dizziness—Paclitaxel—ovarian cancer	0.000432	0.00171	CcSEcCtD
Bumetanide—Vomiting—Paclitaxel—ovarian cancer	0.000415	0.00164	CcSEcCtD
Bumetanide—Rash—Paclitaxel—ovarian cancer	0.000412	0.00163	CcSEcCtD
Bumetanide—Dermatitis—Paclitaxel—ovarian cancer	0.000411	0.00162	CcSEcCtD
Bumetanide—Vertigo—Epirubicin—ovarian cancer	0.000411	0.00162	CcSEcCtD
Bumetanide—Leukopenia—Epirubicin—ovarian cancer	0.000409	0.00162	CcSEcCtD
Bumetanide—Headache—Paclitaxel—ovarian cancer	0.000409	0.00162	CcSEcCtD
Bumetanide—Muscle spasms—Doxorubicin—ovarian cancer	0.000407	0.00161	CcSEcCtD
Bumetanide—Asthenia—Docetaxel—ovarian cancer	0.000397	0.00157	CcSEcCtD
Bumetanide—Pruritus—Docetaxel—ovarian cancer	0.000391	0.00155	CcSEcCtD
Bumetanide—Arthralgia—Epirubicin—ovarian cancer	0.000389	0.00154	CcSEcCtD
Bumetanide—Chest pain—Epirubicin—ovarian cancer	0.000389	0.00154	CcSEcCtD
Bumetanide—Nausea—Paclitaxel—ovarian cancer	0.000388	0.00153	CcSEcCtD
Bumetanide—Dry mouth—Epirubicin—ovarian cancer	0.000381	0.0015	CcSEcCtD
Bumetanide—Vertigo—Doxorubicin—ovarian cancer	0.00038	0.0015	CcSEcCtD
Bumetanide—Leukopenia—Doxorubicin—ovarian cancer	0.000379	0.0015	CcSEcCtD
Bumetanide—Diarrhoea—Docetaxel—ovarian cancer	0.000379	0.0015	CcSEcCtD
Bumetanide—Dizziness—Docetaxel—ovarian cancer	0.000366	0.00145	CcSEcCtD
Bumetanide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000365	0.00144	CcSEcCtD
Bumetanide—Hyperhidrosis—Epirubicin—ovarian cancer	0.000361	0.00143	CcSEcCtD
Bumetanide—Arthralgia—Doxorubicin—ovarian cancer	0.00036	0.00142	CcSEcCtD
Bumetanide—Chest pain—Doxorubicin—ovarian cancer	0.00036	0.00142	CcSEcCtD
Bumetanide—Dry mouth—Doxorubicin—ovarian cancer	0.000352	0.00139	CcSEcCtD
Bumetanide—Vomiting—Docetaxel—ovarian cancer	0.000352	0.00139	CcSEcCtD
Bumetanide—Rash—Docetaxel—ovarian cancer	0.000349	0.00138	CcSEcCtD
Bumetanide—Hypotension—Epirubicin—ovarian cancer	0.000349	0.00138	CcSEcCtD
Bumetanide—Dermatitis—Docetaxel—ovarian cancer	0.000349	0.00138	CcSEcCtD
Bumetanide—Headache—Docetaxel—ovarian cancer	0.000347	0.00137	CcSEcCtD
Bumetanide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000338	0.00134	CcSEcCtD
Bumetanide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000334	0.00132	CcSEcCtD
Bumetanide—Nausea—Docetaxel—ovarian cancer	0.000329	0.0013	CcSEcCtD
Bumetanide—Hypotension—Doxorubicin—ovarian cancer	0.000323	0.00127	CcSEcCtD
Bumetanide—Fatigue—Epirubicin—ovarian cancer	0.000322	0.00127	CcSEcCtD
Bumetanide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000305	0.00121	CcSEcCtD
Bumetanide—Fatigue—Doxorubicin—ovarian cancer	0.000298	0.00118	CcSEcCtD
Bumetanide—Urticaria—Epirubicin—ovarian cancer	0.000296	0.00117	CcSEcCtD
Bumetanide—Abdominal pain—Epirubicin—ovarian cancer	0.000295	0.00117	CcSEcCtD
Bumetanide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000282	0.00112	CcSEcCtD
Bumetanide—Urticaria—Doxorubicin—ovarian cancer	0.000274	0.00108	CcSEcCtD
Bumetanide—Abdominal pain—Doxorubicin—ovarian cancer	0.000273	0.00108	CcSEcCtD
Bumetanide—Asthenia—Epirubicin—ovarian cancer	0.000268	0.00106	CcSEcCtD
Bumetanide—Pruritus—Epirubicin—ovarian cancer	0.000264	0.00104	CcSEcCtD
Bumetanide—Diarrhoea—Epirubicin—ovarian cancer	0.000255	0.00101	CcSEcCtD
Bumetanide—Asthenia—Doxorubicin—ovarian cancer	0.000248	0.000979	CcSEcCtD
Bumetanide—Dizziness—Epirubicin—ovarian cancer	0.000247	0.000975	CcSEcCtD
Bumetanide—Pruritus—Doxorubicin—ovarian cancer	0.000244	0.000965	CcSEcCtD
Bumetanide—Vomiting—Epirubicin—ovarian cancer	0.000237	0.000937	CcSEcCtD
Bumetanide—Diarrhoea—Doxorubicin—ovarian cancer	0.000236	0.000933	CcSEcCtD
Bumetanide—Rash—Epirubicin—ovarian cancer	0.000235	0.00093	CcSEcCtD
Bumetanide—Dermatitis—Epirubicin—ovarian cancer	0.000235	0.000929	CcSEcCtD
Bumetanide—Headache—Epirubicin—ovarian cancer	0.000234	0.000924	CcSEcCtD
Bumetanide—Dizziness—Doxorubicin—ovarian cancer	0.000228	0.000902	CcSEcCtD
Bumetanide—Nausea—Epirubicin—ovarian cancer	0.000222	0.000876	CcSEcCtD
Bumetanide—Vomiting—Doxorubicin—ovarian cancer	0.00022	0.000867	CcSEcCtD
Bumetanide—Rash—Doxorubicin—ovarian cancer	0.000218	0.00086	CcSEcCtD
Bumetanide—Dermatitis—Doxorubicin—ovarian cancer	0.000218	0.000859	CcSEcCtD
Bumetanide—Headache—Doxorubicin—ovarian cancer	0.000216	0.000855	CcSEcCtD
Bumetanide—Nausea—Doxorubicin—ovarian cancer	0.000205	0.00081	CcSEcCtD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.38e-05	0.00133	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.34e-05	0.00133	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	6.26e-05	0.00131	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	6.26e-05	0.00131	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	6.26e-05	0.00131	CbGpPWpGaD
Bumetanide—CA12—Metabolism—FASN—ovarian cancer	6.25e-05	0.00131	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	6.15e-05	0.00129	CbGpPWpGaD
Bumetanide—CA12—Metabolism—SLC5A5—ovarian cancer	6.15e-05	0.00128	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CYP1B1—ovarian cancer	6.15e-05	0.00128	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—CYP1B1—ovarian cancer	6.15e-05	0.00128	CbGpPWpGaD
Bumetanide—CA4—Metabolism—YAP1—ovarian cancer	6.11e-05	0.00128	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	6.09e-05	0.00127	CbGpPWpGaD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.08e-05	0.00127	CbGpPWpGaD
Bumetanide—SLC22A11—Transmembrane transport of small molecules—ABCB1—ovarian cancer	6.08e-05	0.00127	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PPP2R1A—ovarian cancer	5.99e-05	0.00125	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	5.97e-05	0.00125	CbGpPWpGaD
Bumetanide—CA12—Metabolism—SLC2A1—ovarian cancer	5.94e-05	0.00124	CbGpPWpGaD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.87e-05	0.00123	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PPP2R1A—ovarian cancer	5.84e-05	0.00122	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.77e-05	0.00121	CbGpPWpGaD
Bumetanide—CA12—Metabolism—CYP1B1—ovarian cancer	5.69e-05	0.00119	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.58e-05	0.00117	CbGpPWpGaD
Bumetanide—CA14—Metabolism—ABCB1—ovarian cancer	5.56e-05	0.00116	CbGpPWpGaD
Bumetanide—SLC22A7—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.52e-05	0.00115	CbGpPWpGaD
Bumetanide—CA14—Metabolism—TYMS—ovarian cancer	5.46e-05	0.00114	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PPP2R1A—ovarian cancer	5.45e-05	0.00114	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PPP2R1A—ovarian cancer	5.45e-05	0.00114	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—ABCB1—ovarian cancer	5.42e-05	0.00113	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—VEGFA—ovarian cancer	5.41e-05	0.00113	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.4e-05	0.00113	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CYTB—ovarian cancer	5.38e-05	0.00112	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—STAT3—ovarian cancer	5.35e-05	0.00112	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—TYMS—ovarian cancer	5.32e-05	0.00111	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CHMP4C—ovarian cancer	5.26e-05	0.0011	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.26e-05	0.0011	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—FASN—ovarian cancer	5.23e-05	0.00109	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.21e-05	0.00109	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	5.14e-05	0.00107	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—SLC5A5—ovarian cancer	5.14e-05	0.00107	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—MAPK3—ovarian cancer	5.11e-05	0.00107	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.08e-05	0.00106	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—ABCB1—ovarian cancer	5.06e-05	0.00106	CbGpPWpGaD
Bumetanide—CA7—Metabolism—ABCB1—ovarian cancer	5.06e-05	0.00106	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PPP2R1A—ovarian cancer	5.05e-05	0.00106	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—NME2—ovarian cancer	5.04e-05	0.00105	CbGpPWpGaD
Bumetanide—CA4—Metabolism—FASN—ovarian cancer	4.98e-05	0.00104	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—TYMS—ovarian cancer	4.97e-05	0.00104	CbGpPWpGaD
Bumetanide—CA7—Metabolism—TYMS—ovarian cancer	4.97e-05	0.00104	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—SLC2A1—ovarian cancer	4.96e-05	0.00104	CbGpPWpGaD
Bumetanide—CA9—Metabolism—YAP1—ovarian cancer	4.94e-05	0.00103	CbGpPWpGaD
Bumetanide—CA4—Metabolism—SLC5A5—ovarian cancer	4.9e-05	0.00102	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.9e-05	0.00102	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	4.89e-05	0.00102	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—MAPK1—ovarian cancer	4.87e-05	0.00102	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.86e-05	0.00102	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	4.79e-05	0.001	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	4.78e-05	0.000998	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	4.77e-05	0.000997	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—CYP1B1—ovarian cancer	4.76e-05	0.000994	CbGpPWpGaD
Bumetanide—CA4—Metabolism—SLC2A1—ovarian cancer	4.74e-05	0.00099	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—BRIP1—ovarian cancer	4.7e-05	0.000983	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PPP1CC—ovarian cancer	4.7e-05	0.000983	CbGpPWpGaD
Bumetanide—CA12—Metabolism—ABCB1—ovarian cancer	4.69e-05	0.00098	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	4.68e-05	0.000977	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	4.67e-05	0.000976	CbGpPWpGaD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.64e-05	0.000969	CbGpPWpGaD
Bumetanide—CA12—Metabolism—TYMS—ovarian cancer	4.6e-05	0.000962	CbGpPWpGaD
Bumetanide—PTGS2—Disease—BCL9—ovarian cancer	4.56e-05	0.000953	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	4.55e-05	0.000951	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CYP1B1—ovarian cancer	4.54e-05	0.000949	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	4.51e-05	0.000943	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	4.43e-05	0.000925	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	4.42e-05	0.000923	CbGpPWpGaD
Bumetanide—CA14—Metabolism—CAV1—ovarian cancer	4.4e-05	0.00092	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—CAV1—ovarian cancer	4.29e-05	0.000896	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.28e-05	0.000894	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PPP2R1A—ovarian cancer	4.22e-05	0.000882	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.2e-05	0.000878	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.12e-05	0.00086	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—TP53—ovarian cancer	4.08e-05	0.000854	CbGpPWpGaD
Bumetanide—CA9—Metabolism—FASN—ovarian cancer	4.03e-05	0.000842	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PPP2R1A—ovarian cancer	4.03e-05	0.000841	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PIK3CG—ovarian cancer	4.01e-05	0.000838	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—CAV1—ovarian cancer	4e-05	0.000837	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CAV1—ovarian cancer	4e-05	0.000837	CbGpPWpGaD
Bumetanide—CA9—Metabolism—SLC5A5—ovarian cancer	3.96e-05	0.000828	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—ABCB1—ovarian cancer	3.92e-05	0.000819	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PIK3CG—ovarian cancer	3.91e-05	0.000817	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.87e-05	0.000809	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—TYMS—ovarian cancer	3.85e-05	0.000804	CbGpPWpGaD
Bumetanide—CA9—Metabolism—SLC2A1—ovarian cancer	3.83e-05	0.0008	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	3.76e-05	0.000786	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	3.75e-05	0.000784	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—IL6—ovarian cancer	3.74e-05	0.000781	CbGpPWpGaD
Bumetanide—CA4—Metabolism—ABCB1—ovarian cancer	3.74e-05	0.000781	CbGpPWpGaD
Bumetanide—CA12—Metabolism—CAV1—ovarian cancer	3.71e-05	0.000775	CbGpPWpGaD
Bumetanide—CA4—Metabolism—TYMS—ovarian cancer	3.67e-05	0.000767	CbGpPWpGaD
Bumetanide—CA9—Metabolism—CYP1B1—ovarian cancer	3.67e-05	0.000767	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	3.65e-05	0.000763	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PIK3CG—ovarian cancer	3.65e-05	0.000762	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PIK3CG—ovarian cancer	3.65e-05	0.000762	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	3.57e-05	0.000746	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	3.57e-05	0.000746	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PIK3CD—ovarian cancer	3.52e-05	0.000737	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3.5e-05	0.000732	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.49e-05	0.000729	CbGpPWpGaD
Bumetanide—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	3.47e-05	0.000725	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PIK3CD—ovarian cancer	3.44e-05	0.000718	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.43e-05	0.000716	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PPP1CC—ovarian cancer	3.39e-05	0.000709	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PIK3CG—ovarian cancer	3.38e-05	0.000706	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PPP2R1A—ovarian cancer	3.25e-05	0.00068	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CYTB—ovarian cancer	3.25e-05	0.000679	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.25e-05	0.000678	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PIK3CD—ovarian cancer	3.21e-05	0.00067	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PIK3CD—ovarian cancer	3.21e-05	0.00067	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3.18e-05	0.000665	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.18e-05	0.000664	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—YAP1—ovarian cancer	3.15e-05	0.000659	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.12e-05	0.000652	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—CAV1—ovarian cancer	3.1e-05	0.000648	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	3.1e-05	0.000647	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PIK3CB—ovarian cancer	3.07e-05	0.000642	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	3.07e-05	0.000641	CbGpPWpGaD
Bumetanide—CA9—Metabolism—ABCB1—ovarian cancer	3.02e-05	0.000631	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	3e-05	0.000627	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PIK3CB—ovarian cancer	2.99e-05	0.000626	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.99e-05	0.000625	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PIK3CD—ovarian cancer	2.97e-05	0.000621	CbGpPWpGaD
Bumetanide—CA9—Metabolism—TYMS—ovarian cancer	2.97e-05	0.00062	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.96e-05	0.000619	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CAV1—ovarian cancer	2.96e-05	0.000618	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PPP1CC—ovarian cancer	2.84e-05	0.000593	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—BRIP1—ovarian cancer	2.84e-05	0.000593	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PIK3CG—ovarian cancer	2.83e-05	0.00059	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PIK3CB—ovarian cancer	2.8e-05	0.000584	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PIK3CB—ovarian cancer	2.8e-05	0.000584	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	2.74e-05	0.000574	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.74e-05	0.000573	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.7e-05	0.000564	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PIK3CG—ovarian cancer	2.7e-05	0.000563	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PTEN—ovarian cancer	2.65e-05	0.000555	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PIK3CB—ovarian cancer	2.59e-05	0.000541	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PTEN—ovarian cancer	2.59e-05	0.000541	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—FASN—ovarian cancer	2.57e-05	0.000537	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HDAC6—ovarian cancer	2.57e-05	0.000537	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.55e-05	0.000534	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—SLC5A5—ovarian cancer	2.53e-05	0.000528	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.48e-05	0.000519	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PIK3CD—ovarian cancer	2.48e-05	0.000519	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—SLC2A1—ovarian cancer	2.44e-05	0.00051	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.43e-05	0.000508	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.43e-05	0.000508	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PTEN—ovarian cancer	2.42e-05	0.000505	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PTEN—ovarian cancer	2.42e-05	0.000505	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.39e-05	0.0005	CbGpPWpGaD
Bumetanide—CA9—Metabolism—CAV1—ovarian cancer	2.39e-05	0.0005	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PIK3CD—ovarian cancer	2.37e-05	0.000495	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CYP1B1—ovarian cancer	2.34e-05	0.000489	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.29e-05	0.00048	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PTEN—ovarian cancer	2.24e-05	0.000468	CbGpPWpGaD
Bumetanide—PTGS2—Disease—XIAP—ovarian cancer	2.23e-05	0.000466	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PIK3CG—ovarian cancer	2.18e-05	0.000455	CbGpPWpGaD
Bumetanide—PTGS2—Disease—SMARCA4—ovarian cancer	2.17e-05	0.000454	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PIK3CB—ovarian cancer	2.16e-05	0.000452	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EREG—ovarian cancer	2.12e-05	0.000443	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.11e-05	0.000441	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PPP2R1A—ovarian cancer	2.08e-05	0.000434	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.07e-05	0.000432	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.07e-05	0.000432	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PIK3CB—ovarian cancer	2.07e-05	0.000432	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.04e-05	0.000426	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—ABCB1—ovarian cancer	1.93e-05	0.000403	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PIK3CD—ovarian cancer	1.91e-05	0.0004	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—YAP1—ovarian cancer	1.9e-05	0.000398	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—TYMS—ovarian cancer	1.89e-05	0.000396	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.88e-05	0.000394	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PIK3CA—ovarian cancer	1.87e-05	0.000391	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PTEN—ovarian cancer	1.87e-05	0.000391	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FASN—ovarian cancer	1.85e-05	0.000387	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PARP1—ovarian cancer	1.85e-05	0.000386	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PIK3CA—ovarian cancer	1.83e-05	0.000381	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PTEN—ovarian cancer	1.78e-05	0.000373	CbGpPWpGaD
Bumetanide—PTGS2—Disease—SLC2A1—ovarian cancer	1.76e-05	0.000368	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.72e-05	0.00036	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PIK3CA—ovarian cancer	1.7e-05	0.000356	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PIK3CA—ovarian cancer	1.7e-05	0.000356	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PIK3CB—ovarian cancer	1.67e-05	0.000349	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.66e-05	0.000346	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PIK3CA—ovarian cancer	1.58e-05	0.00033	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—FASN—ovarian cancer	1.55e-05	0.000324	CbGpPWpGaD
Bumetanide—CA14—Metabolism—AKT1—ovarian cancer	1.53e-05	0.00032	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—SLC5A5—ovarian cancer	1.53e-05	0.000319	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CAV1—ovarian cancer	1.53e-05	0.000319	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PPP2R1A—ovarian cancer	1.5e-05	0.000313	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—AKT1—ovarian cancer	1.49e-05	0.000312	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—SLC2A1—ovarian cancer	1.47e-05	0.000308	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.46e-05	0.000305	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.44e-05	0.000302	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PTEN—ovarian cancer	1.44e-05	0.000301	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CYP1B1—ovarian cancer	1.41e-05	0.000295	CbGpPWpGaD
Bumetanide—CA7—Metabolism—AKT1—ovarian cancer	1.39e-05	0.000291	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—AKT1—ovarian cancer	1.39e-05	0.000291	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PIK3CG—ovarian cancer	1.39e-05	0.00029	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PIK3CA—ovarian cancer	1.32e-05	0.000276	CbGpPWpGaD
Bumetanide—CA12—Metabolism—AKT1—ovarian cancer	1.29e-05	0.000269	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PIK3CA—ovarian cancer	1.26e-05	0.000263	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PPP2R1A—ovarian cancer	1.25e-05	0.000262	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.25e-05	0.000261	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PIK3CD—ovarian cancer	1.22e-05	0.000255	CbGpPWpGaD
Bumetanide—PTGS2—Disease—TERT—ovarian cancer	1.19e-05	0.000249	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—ABCB1—ovarian cancer	1.16e-05	0.000243	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—TYMS—ovarian cancer	1.14e-05	0.000239	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CAV1—ovarian cancer	1.1e-05	0.00023	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—AKT1—ovarian cancer	1.08e-05	0.000225	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	1.07e-05	0.000223	CbGpPWpGaD
Bumetanide—PTGS2—Disease—IL6ST—ovarian cancer	1.04e-05	0.000218	CbGpPWpGaD
Bumetanide—CA4—Metabolism—AKT1—ovarian cancer	1.03e-05	0.000215	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PIK3CA—ovarian cancer	1.02e-05	0.000213	CbGpPWpGaD
Bumetanide—PTGS2—Disease—APC—ovarian cancer	1e-05	0.000209	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CAV1—ovarian cancer	9.22e-06	0.000193	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PTEN—ovarian cancer	9.2e-06	0.000192	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PIK3CD—ovarian cancer	8.81e-06	0.000184	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.8e-06	0.000184	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PIK3CG—ovarian cancer	8.39e-06	0.000175	CbGpPWpGaD
Bumetanide—CA9—Metabolism—AKT1—ovarian cancer	8.31e-06	0.000174	CbGpPWpGaD
Bumetanide—PTGS2—Disease—ERBB2—ovarian cancer	7.78e-06	0.000163	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PIK3CB—ovarian cancer	7.68e-06	0.00016	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MTOR—ovarian cancer	7.68e-06	0.00016	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PIK3CD—ovarian cancer	7.38e-06	0.000154	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CDKN1B—ovarian cancer	7.21e-06	0.000151	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CTNNB1—ovarian cancer	6.81e-06	0.000142	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PTEN—ovarian cancer	6.64e-06	0.000139	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	6.49e-06	0.000136	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PIK3CB—ovarian cancer	6.43e-06	0.000134	CbGpPWpGaD
Bumetanide—PTGS2—Disease—STAT3—ovarian cancer	5.94e-06	0.000124	CbGpPWpGaD
Bumetanide—PTGS2—Disease—NRAS—ovarian cancer	5.92e-06	0.000124	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MAPK3—ovarian cancer	5.67e-06	0.000118	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PTEN—ovarian cancer	5.56e-06	0.000116	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MYC—ovarian cancer	5.52e-06	0.000115	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MAPK1—ovarian cancer	5.4e-06	0.000113	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EGFR—ovarian cancer	5.39e-06	0.000113	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—AKT1—ovarian cancer	5.3e-06	0.000111	CbGpPWpGaD
Bumetanide—PTGS2—Disease—KRAS—ovarian cancer	5.1e-06	0.000106	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PIK3CA—ovarian cancer	4.68e-06	9.78e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HRAS—ovarian cancer	4.33e-06	9.05e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—IL6—ovarian cancer	4.15e-06	8.66e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PIK3CA—ovarian cancer	3.92e-06	8.19e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AKT1—ovarian cancer	3.82e-06	7.99e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—AKT1—ovarian cancer	3.2e-06	6.69e-05	CbGpPWpGaD
